Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Sexual Dysfunction, Physiological 1Neuroma, Acoustic 1Neurofibromatosis 2 1Meningioma 1Lymphoma, Large-Cell, Anaplastic 1Granuloma, Plasma Cell 1Eunuchism 1Erectile Dysfunction 1Ependymoma 1

Interventions

lutetium Lu 177 dotatate 2Temozolomide 2ONC206 2Etoposide 2Cyclophosphamide 2Bevacizumab 2olaparib 1neratinib 1ibrutinib 1fenofibric acid 1etoposide phosphate 1brigatinib 1Watchful Waiting 1Thalidomide 1Restraint, Physical 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Linear Energy Transfer 1Irinotecan 1Elasticity Imaging Techniques 1Cytarabine 1Celecoxib 1Automobiles 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ependymoma × brigatinib × Clear all
NCT04374305 2026-05-06

INTUITT-NF2

Massachusetts General Hospital

Phase 2 Recruiting
109 enrolled
CNS

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡